Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!

>

MEETINGS / EVENTS

RSS

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

Summary:

FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur

Summary:

FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled

Summary:

Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

Generic Drug Industry Proposal to Address Drug Shortages Gets FTC Approval

Friday, August 10, 2012

The Generic Pharmaceutical Association (GPhA) received a Federal Trade Commission (FTC) Advisory Opinion permitting a plan to address drug shortages to move forward.  The GPhA’s plan is titled the "Accelerated Recovery Initiative (ARI)," and it would operate by generic drug manufacturers communicating production details of critical drugs to health care technology company, IMS Health.  This information would be pooled together with other IMS Health market data and then shared with the Food and Drug Administration.  Reportedly, with this information, the FDA would have a comprehensive real time view of drug production in the generic market place and could work more quickly and efficiently to avert shortages.

The announcement of the FTC's Advisory Opinion citing no antitrust violations with this ARI plan comes in the wake of the recently passed "Food and Drug Administration Safety Act," which placed a high value on enhanced notification of drug shortages. 

More about drug shortages.

« Back to Washington Alerts